Evaluation of the Effect of L-Arginine on the Cognitive Function in Geriatric Patients
Evaluation of the Effect of L-Arginine on the Cognitive Function in Geriatric Patients, A Randomized Clinical Trial
German University in Cairo
60 participants
Aug 27, 2025
INTERVENTIONAL
Conditions
Summary
This study aims to evaluate the effect of L-arginine supplementation on cognitive function in geriatric patients. Eligible participants will receive either L-arginine (6 grams once daily) or placebo, and their cognitive performance will be assessed using validated cognitive assessment tools over the study period. The participants will receive the intervention for 4 weeks and followed up every 2 weeks. The primary outcome is improvement in cognitive function, while secondary outcomes include safety, tolerability, and quality of life measures. The findings may provide evidence for the potential role of L-arginine in supporting cognitive health in elderly populations.
Eligibility
Inclusion Criteria2
- Age >60 years
- Montreal Cognitive Assessment (MoCA) test score from 10-25 (mild to moderate cognitive impairment)
Exclusion Criteria12
- Presence of neurodegenerative diseases (e.g.: Alzheimer's disease, Parkinson's disease, Huntington's disease, Multiple Sclerosis)
- Patients with history of L-arginine intolerance or allergy
- Patients with asthma
- Patients who recently had an acute myocardial infarction
- Patients with history of stroke within 1 yaear
- Patients who started or discontinued medications that may affect cognitive function (e.g., CNS psychotropics, antihistamines, or acetylcholinesterase inhibitors) during the study period.
- Patients who initiated or stopped antihypertensive medications during the study period.
- Patients who initiated or stopped antidiabetic medications during the study period.
- Patients who initiated or stopped antihyperlipidemic medications during the study period.
- Patients prescribed medications for depression, anxiety, or stress that may impact cognitive function
- Patients on nitrates, phosphodiesterase-5 inhibitors, potassium sparing diuretics
- Refusal to provide written informed consent
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
6 grams L-arginine sachets taken orally once daily
Matching Placebo of L-arginine
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07338682